Bevacizumab biosimilar LY01008 compared with bevacizumab (Avastin) as first‐line treatment for Chinese patients with unresectable, metastatic, or recurrent non‐squamous non–small‐cell lung cancer: A multicenter, randomized, double‐blinded, phase III trial

Previous studies have demonstrated the preclinical pharmacological and toxicological consistency, and clinical pharmacokinetic equivalence of bevacizumab biosimilar LY01008 with reference bevacizumab (Avastin). This randomized controlled trial aimed to compare the efficacy and safety of LY01008 with Avastin in first‐line treatment of Chinese patients with advanced or recurrent non‐squamous non‐small cell lung cancer (NSCLC).

[1]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[2]  [Clinical practice guideline for stage Ⅳ primary lung cancer in China(2021 version)]. , 2021, Zhonghua zhong liu za zhi [Chinese journal of oncology].

[3]  B. Wu,et al.  Atezolizumab plus bevacizumab versus sorafenib as first‐line treatment for unresectable hepatocellular carcinoma: a cost‐effectiveness analysis , 2020, Cancer communications.

[4]  Yuankai Shi,et al.  Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001–2020) , 2020, Journal of Hematology & Oncology.

[5]  M. Socinski,et al.  IMpower150: Exploratory analysis of brain metastases development. , 2020 .

[6]  Wanqing Chen,et al.  Cancer burden of major cancers in China: A need for sustainable actions , 2020, Cancer communications.

[7]  Ying Cheng,et al.  Biosimilar candidate IBI305 plus paclitaxel/carboplatin for the treatment of non-squamous non-small cell lung cancer. , 2019, Translational lung cancer research.

[8]  N. Reinmuth,et al.  PF-06439535 (a Bevacizumab Biosimilar) Compared with Reference Bevacizumab (Avastin®), Both Plus Paclitaxel and Carboplatin, as First-Line Treatment for Advanced Non-Squamous Non-Small-Cell Lung Cancer: A Randomized, Double-Blind Study , 2019, BioDrugs.

[9]  C. Gessner,et al.  AVAiLABLE NIS – AVASTIN® in lung cancer treatment in routine oncology practice in Germany , 2019, BMC Cancer.

[10]  B. Han,et al.  A multi-center, randomized, double-blind, parallel, two-group phase III clinical study on the efficacy and safety of QL1101 or bevacizumab in combination with paclitaxel and carboplatin in the first-line treatment of non-squamous non-small cell lung cancer. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[11]  Michael Thomas,et al.  Efficacy and Safety of the Biosimilar ABP 215 Compared with Bevacizumab in Patients with Advanced Nonsquamous Non–small Cell Lung Cancer (MAPLE): A Randomized, Double-blind, Phase III Study , 2019, Clinical Cancer Research.

[12]  Federico Cappuzzo,et al.  Atezolizumab for First‐Line Treatment of Metastatic Nonsquamous NSCLC , 2018, The New England journal of medicine.

[13]  Y. Shi,et al.  [The development of biosimilars in oncology]. , 2017, Zhonghua zhong liu za zhi [Chinese journal of oncology].

[14]  B. Monk,et al.  Barriers to the Access of Bevacizumab in Patients with Solid Tumors and the Potential Impact of Biosimilars: A Physician Survey , 2017, Pharmaceuticals.

[15]  Yang Zhang,et al.  中国肺癌脑转移诊治专家共识（2017年版） , 2017, Zhongguo fei ai za zhi = Chinese journal of lung cancer.

[16]  R. Sullivan,et al.  ESMO European Consortium Study on the availability, out-of-pocket costs and accessibility of antineoplastic medicines in Europe. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[17]  A. Jemal,et al.  Cancer statistics in China, 2015 , 2016, CA: a cancer journal for clinicians.

[18]  H. Zhang,et al.  BEYOND: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of First-Line Carboplatin/Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients With Advanced or Recurrent Nonsquamous Non-Small-Cell Lung Cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  V. Anagnostou,et al.  Cancer Immunotherapy: A Future Paradigm Shift in the Treatment of Non–Small Cell Lung Cancer , 2015, Clinical Cancer Research.

[20]  J. Armitage,et al.  Regulatory and clinical considerations for biosimilar oncology drugs. , 2014, The Lancet. Oncology.

[21]  L. Crinò,et al.  Therapeutic options targeting angiogenesis in nonsmall cell lung cancer , 2014, European Respiratory Review.

[22]  K. Rabe,et al.  Management of non-small-cell lung cancer: recent developments , 2013, The Lancet.

[23]  Tianhong Li,et al.  Genotyping and genomic profiling of non-small-cell lung cancer: implications for current and future therapies. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  S. Ramsey,et al.  A trial-based assessment of the cost-utility of bevacizumab and chemotherapy versus chemotherapy alone for advanced non-small cell lung cancer. , 2010, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[25]  R. Ramlau,et al.  Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  Richard Pazdur,et al.  FDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer. , 2007, The oncologist.

[27]  Robert Gray,et al.  Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. , 2006, The New England journal of medicine.

[28]  S. Thibodeau,et al.  Clinical features of 5,628 primary lung cancer patients: experience at Mayo Clinic from 1997 to 2003. , 2005, Chest.

[29]  N. Ferrara.  Vascular endothelial growth factor as a target for anticancer therapy. , 2004, The oncologist.

[30]  N. Ferrara,et al.  The biology of VEGF and its receptors , 2003, Nature Medicine.

[31]  David Harrington,et al.  Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. , 2002, The New England journal of medicine.

[32]  J. Folkman,et al.  ISOLATION OF A TUMOR FACTOR RESPONSIBLE FOR ANGIOGENESIS , 1971, The Journal of experimental medicine.

[33]  Richard M. Johnson.  Guideline on similar biological medicinal products , 2010 .

[34]  English Only,et al.  GUIDELINES ON EVALUATION OF SIMILAR BIOTHERAPEUTIC PRODUCTS (SBPs) , 2009 .